Last reviewed · How we verify
ATTO-3712
At a glance
| Generic name | ATTO-3712 |
|---|---|
| Sponsor | Attovia Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATTO-3712 CI brief — competitive landscape report
- ATTO-3712 updates RSS · CI watch RSS
- Attovia Therapeutics Inc portfolio CI